Diva Total

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diva Total

Quick Facts

Property Description
Active Ingredients Drospirenone (Progestin) and Ethinyl Estradiol (Estrogen)
Form Oral Tablets (Film-Coated)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic (Lab-Made Hormones)

1. Diva Total: Definition and Pharmacological Classification

Diva Total is a prescription-only combined hormonal contraceptive (CHC), an oral medicine used to prevent pregnancy. It is categorized within the pharmacological class of progestogen and estrogen combinations, utilizing two distinct, synthetic hormone compounds to achieve its systemic effect. The two active ingredients, Drospirenone and Ethinyl Estradiol, are entirely synthetic in origin, and the medicine is supplied in the solid dosage form of film-coated tablets for oral administration. This specific combination is clinically recognized, with indications for this formulation in contraception.

2. Active Components: Differentiation and Profile

The medicine's efficacy relies on Ethinyl Estradiol (a synthetic estrogen) and Drospirenone (a synthetic progestin). Drospirenone is classified as a fourth-generation progestin, a distinction based on its unique pharmacological properties. These properties include both antimineralocorticoid and antiandrogenic activity. The antimineralocorticoid action is a differentiating factor, as it helps regulate the balance of water and salt, which is a property that sets it apart from older progestins. This unique hormonal profile is relevant for women seeking contraception alongside management of conditions like mild acne.

3. The Core Purpose: Multi-Action Contraception

The fundamental purpose of Diva Total is contraception, achieved through a highly effective, multi-level mechanism. The two hormones operate in concert, with the primary action being the inhibition of ovulation, effectively preventing the monthly release of an egg. Additionally, the active components alter the cervical mucus consistency, creating a barrier that impedes sperm movement, and modify the uterine lining to reduce its receptivity. These physiological effects collectively ensure robust prevention of pregnancy in women of reproductive potential.

What side effects are possible with Diva Total?

Possible Side Effects and Safety Information

The official safety profile for the drospirenone/ethinyl estradiol combination is structured around high-level frequency classifications and serious, clinically significant risks as documented by regulatory authorities. The adverse reactions are categorized by their expected incidence rate and the body system affected.

Frequency-Classified Adverse Reactions

Side effects observed in clinical data are grouped based on frequency, with the most commonly reported events classified as Very Common (occurring in 10% or more of users), which include headache and breast pain or discomfort. Adverse reactions listed as Common (occurring in 1% to <10% of users) include nausea, migraine, depressive mood, affect lability, and increased weight.

Classification System-Organ Classes Affected
Very Common Nervous System; Reproductive System & Breast
Common Gastrointestinal; Psychiatric; Skin; Metabolic

Serious Safety Risks and Contraindications

The most serious documented safety concerns involve thromboembolic disorders. The use of combined hormonal contraceptives is associated with an increased risk of Venous Thromboembolism (e.g., DVT and Pulmonary Embolism) and Arterial Thrombotic Events (e.g., Stroke and Myocardial Infarction). Regulatory documents indicate this risk is highest during the first year of use or upon restarting after an extended break.

Specific contraindications are related to the drospirenone component’s antimineralocorticoid activity, which carries a risk of Hyperkalemia (high potassium levels). Therefore, the medication is explicitly contraindicated in patients with renal impairment, adrenal insufficiency, or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Drospirenone and Ethinyl Estradiol describes a specific profile for overdosage. While acute exposures may not always result in severe effects, immediate medical attention is required for any suspected overdose.

Documented Overdose Manifestations

System Manifestation
Gastrointestinal Nausea and vomiting
Reproductive Vaginal bleeding (withdrawal bleeding)

Required Emergency Actions

The management of overdose is symptomatic and supportive, as official labeling states that no specific antidote is known. Due to the presence of Drospirenone, a component with anti-mineralocorticoid activity, the regulatory profile highlights a critical risk of electrolyte imbalance, specifically hyperkalemia (elevated potassium).

Immediate medical help must be sought in all cases of suspected overdose. During emergency care, procedures often involve monitoring serum potassium levels and assessing for signs of metabolic acidosis, particularly in patients with pre-existing conditions that predispose them to high potassium levels, such as renal, hepatic, or adrenal impairment. Contacting a poison control center or emergency services is the mandated immediate step.

Therapeutic Uses of Diva Total

What Diva Total Treats: Main Uses and Benefits

Diva Total is commonly used across three therapeutic domains: to provide prevention of pregnancy, to treat the symptoms of Premenstrual Dysphoric Disorder (PMDD), and to treat moderate acne vulgaris.

The primary benefit is in managing the reproductive cycle, which provides support for managing the risk of unintended pregnancy. For women experiencing severe cyclical symptoms, the medication is relevant for managing intense symptom clusters, including mood instability, anxiety, and depressive feelings, as well as physical manifestations like bloating and breast tenderness. This therapeutic profile means the patient can be considered for contraception alongside specialized relief.

“It is a therapeutic choice that may assist with easing challenging physical and emotional manifestations that interfere with daily functioning.”

Quick Fact: Relief for Cyclical Discomfort and Skin Irregularities

Symptom Focus Therapeutic Benefit
PMDD Symptoms May support improved comfort during periods of heightened premenstrual distress.
Moderate Acne May assist with easing the symptom load associated with moderate acne.
Fertility Risk Provides support for managing the risk of unintended pregnancy.

Regulatory References

  1. DailyMed drug information from the National Institutes of Health

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Diva Total?

The official regulatory information for Diva Total (Drospirenone and Ethinyl Estradiol) clearly defines the populations for whom use is permitted, restricted, or absolutely prohibited.

Contraindicated Populations

This medicine is contraindicated and must not be used by individuals with certain risk factors or health conditions. These include women over age 35 who smoke, those with a history of blood clots (such as DVT or PE), stroke, or coronary artery disease. Use is also prohibited for those with specific hormone-sensitive cancers (like breast cancer), liver tumors, severe liver disease, renal impairment, or adrenal insufficiency. Diva Total is also contraindicated during pregnancy.

Eligibility and Restricted Use

Use is established for females of reproductive potential, including postpubertal adolescents. However, the medicine is not indicated for use in elderly women (ge 65 years of age). Eligibility is subject to timing restrictions: the medicine must be discontinued at least four weeks before and for two weeks after major surgery. For non-breastfeeding women, the start date must be at least four weeks postpartum. Additionally, the medicine is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The officially documented interaction profile for Diva Total is defined by pharmacokinetic and pharmacodynamic mechanisms that dictate specific co-administration restrictions.

Strict Regulatory Contraindications:

  • Co-administration is formally prohibited with specific Hepatitis C drug combinations, including regimens containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir.
  • Oral Tranexamic Acid is also contraindicated due to a documented pharmacodynamic synergism that increases the risk of thromboembolic events.

Clinically Significant Interactions: The hormonal components are subject to hepatic enzyme activity:

  • Enzyme Inducers (e.g., Rifampicin, St. John’s Wort herbal product) accelerate metabolism, resulting in decreased plasma exposure and reduced contraceptive effectiveness.
  • Strong CYP3A4 Inhibitors (e.g., Ketoconazole) increase the systemic exposure of the Drospirenone component.

Pharmacodynamic Risk: Drospirenone possesses anti-mineralocorticoid activity. This creates a documented risk of hyperkalemia when co-administered with other potassium-increasing medications, such as ACE inhibitors, Angiotensin-II receptor antagonists, and potassium-sparing diuretics. Monitoring of serum potassium levels is required during the initial cycle when strong CYP3A4 inhibitors are co-administered long-term.

Substance and Population Notes:

  • Grapefruit Juice consumption is documented to increase the exposure of the Ethinyl Estradiol component.
  • The hyperkalemia interaction risk is significantly heightened in populations with renal impairment, hepatic impairment, or adrenal insufficiency, which are formal contraindications for use.

Mechanism of Action

The action of Diva Total is defined by its precise interaction with key biological systems, working to modulate dysregulated processes at the molecular level. Its mechanism is characterized by targeted engagement within specific signaling pathways, which results in alterations to signal transmission within the targeted system.

Targeted Receptor and Enzyme Modulation

Diva Total operates primarily by engaging defined receptor systems or enzymatic targets. This interaction alters the responsiveness of these targets to natural signaling molecules, initiating a process of targeted pathway interference.

Altering Signaling Pathway Dynamics

Following initial binding, the drug focuses on altering the subsequent intracellular signaling dynamics across relevant neural or humoral pathways. By modifying the cascade of molecular events, Diva Total results in the dampening of excessive signal transduction within systems where specific transmitters or mediators dominate the physiological response.

Regulating Physiological Systems

The cumulative effect of targeted molecular action is the regulation of overactive or dysregulated physiological responses. This mechanism operates to adjust systems where heightened pathway activation exists, thereby influencing the resulting pattern of physiological activity.

Dosage and Administration Information

Diva Total is administered daily via the oral route following a highly structured 28-day cycle. The standard regimen for all labeled uses requires taking one film-coated tablet by mouth at approximately the same time every day. The pack structure mandates sequential use of 24 active light pink tablets (containing 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol) followed by 4 white inert tablets (placebo).

Administration must strictly follow the order directed on the blister pack, maintaining daily consistency. The medication can be taken without regard to meals, though taking it after the evening meal or at bedtime is often noted in official guidance. The treatment pattern is long-term and continuous: a new 28-day pack must be started immediately after the last tablet of the previous pack, without any tablet-free interval.

For initial use, a patient may choose a Day 1 Start (first day of menses) or a Sunday Start. If the first cycle is initiated later than Day 1, a non-hormonal back-up method must be used for the first seven consecutive days of active tablet intake. Specific procedures, detailed in the patient information, govern the handling of any missed active tablets, based on how many were missed and the week of the cycle. This structured protocol is designed to standardize administration across the relevant female population, as the medication is not indicated for use after menopause.

Recent Clinical Evidence

Research evidence / Overview of studies for Diva Total

This overview summarizes the available research and clinical trials conducted to evaluate the use of Diva Total. This information reflects the evidence structure and is not intended to provide medical advice or instructions.


Evidence for Use in Contraception

Research for pregnancy prevention relied on extensive Phase III randomized trials and long-term observational settings. These studies were designed to measure the medicine's failure rate (Pearl Index) and assess menstrual cycle control in healthy women of reproductive potential. While a substantial amount of data exists regarding this clinical situation, long-term outcomes for certain rare events are not fully established by randomized trials alone, relying instead on post-marketing surveillance.


Evidence for Management of Premenstrual Dysphoric Disorder (PMDD)

Research explored symptoms associated with PMDD using short-term randomized, double-blind, placebo-controlled trials. The outcomes studied included measurements of symptom severity using daily rating scales for women with a confirmed PMDD diagnosis. However, follow-up durations were typically limited to three consecutive cycles, meaning long-term effects are not fully established regarding sustained symptom patterns beyond this initial short period.


Evidence for Management of Moderate Acne Vulgaris

The medicine was evaluated in multicenter, double-blind, randomized, placebo-controlled studies focusing on moderate facial acne. Findings described specific measurements of lesion counts and overall skin condition scores that were tracked and compared to placebo. The research applies only to the populations studied: females who were also seeking a prescription contraceptive, and limited information exists on sustained skin improvement after the initial six-month trial period.


Evidence Quality and Research Gaps

While the evidence base for contraception and moderate acne is derived from multiple randomized trial patterns, evidence quality varies across studies for the PMDD indication. Key research gaps include the limited information for long-term outcomes regarding the sustained nature of the effects observed for both PMDD and acne. Additionally, data for certain groups, such as geriatric populations or women with less severe forms of premenstrual distress, remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Diva Total (FAQ)


Q: How long does it typically take to feel the initial effects of Diva Total?

According to official product information, Diva Total is not considered fully effective for pregnancy prevention until after the first 7 consecutive days of active tablet use. Compliance with the prescribed administration schedule is described as important during this initial period. For other medical uses, the precise timeline for feeling the initial effects is generally not detailed in patient information.


Q: How do other prescription medicines affect the effectiveness of Diva Total?

Official warnings note that certain prescription medicines can either increase or decrease the hormones in Diva Total. Certain medications, such as enzyme inducers, are documented to reduce the hormonal exposure, which may lead to reduced contraceptive effectiveness. Conversely, some enzyme inhibitors can increase the overall exposure to the drospirenone component.


Q: Is Diva Total use described differently for individuals with liver or kidney conditions?

Yes, official regulatory documents state that Diva Total is contraindicated (should not be used) in individuals who have renal impairment (kidney problems), hepatic impairment (liver problems), or adrenal insufficiency. This is due to the drospirenone component’s unique action, which is associated with a risk of developing high potassium levels (hyperkalemia) in these populations.


Q: Can taking Diva Total for a long period of time lead to bone health issues?

Official product information for this medication does not require a specific warning about long-term bone health issues. However, studies on the general class of hormonal contraceptives have historically examined the potential effect on bone mineral density (BMD), particularly in adolescents. Concerns regarding long-term use should be discussed with a healthcare professional.


Q: Does Diva Total cause drowsiness or affect a person's ability to focus?

Drowsiness (somnolence) and dizziness have been reported as uncommon side effects in clinical trials for this medication. Furthermore, reported adverse reactions like headache and migraine may also affect a person's concentration.


Q: What is the recommended approach if a person misses a single dose of Diva Total?

Official patient instructions detail specific protocols based on the number of tablets missed and the week of the cycle. Generally, if one active tablet is missed, it should be taken as soon as it is remembered, with the next tablet taken at the regular time. Missing two or more active tablets may require the use of a back-up contraceptive method, with the exact procedure detailed in the patient information.


Q: Is Diva Total described as having a risk of physical dependence?

The official product labeling and regulatory documents for Diva Total do not include warnings or specific information concerning the development of physical dependence or substance abuse potential.


Q: Does Diva Total affect mood or cause significant emotional changes?

Yes, clinical trials report that both depressive mood and affect lability (unstable emotions) are common adverse reactions. Additionally, nervousness and changes in libido have been reported. This information is noted in the official safety profile for the medication.


Q: What types of over-the-counter medicines are known to interact with Diva Total?

Official warnings note that taking Diva Total with certain over-the-counter medications, particularly NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), may increase the risk of high potassium levels (hyperkalemia) in susceptible individuals. It is advised to review potential interactions with any over-the-counter product with a healthcare professional.


Q: Can Diva Total affect vision or cause changes in eye health?

Official product labeling includes warnings regarding the possibility of visual abnormalities and states that changes in vision or intolerance to contact lenses should be monitored. Regulatory guidance indicates that changes in vision or intolerance to contact lenses should be assessed by a healthcare professional.


Q: Is Diva Total appropriate for use in the elderly population?

No. Diva Total is specifically indicated for use by females of reproductive potential and is not indicated for use in women 65 years of age and older. Use is intended to cease when a woman reaches the age of menopause.


Q: Is it possible to use Diva Total with a previously prescribed medication from a different category?

Official regulatory documents define a number of drug interactions, some of which are formally prohibited (contraindicated), such as specific Hepatitis C drug regimens. Other interactions may require close monitoring or the use of a back-up contraceptive method. The official guidance emphasizes that a full review of all current medications is necessary before starting Diva Total.


Q: Are there mandatory blood tests or lab checks recommended when using Diva Total?

Monitoring of serum potassium concentration is documented to be required during the first treatment cycle for individuals who are also taking certain other long-term medications that increase potassium levels. This is due to the anti-mineralocorticoid activity of the drospirenone component.


Q: Does Diva Total have any described effect on sleep patterns?

Insomnia (difficulty sleeping) has been reported as a rare adverse reaction in the post-marketing experience of this medication.


Q: Is the drug known to cause hair loss as a side effect?

Alopecia (hair loss) is reported as an uncommon side effect in the clinical data available for this medication.


Q: Are there any specific lifestyle factors (e.g., smoking) mentioned in the official warnings for Diva Total?

Cigarette smoking is a major safety concern. The official boxed warning states that smoking significantly increases the risk of serious cardiovascular events, particularly in women over 35 years of age. For this reason, the medication is formally contraindicated for use in women over 35 who smoke.


Q: Can Diva Total affect dental or oral health in any described way?

Gingivitis (inflammation of the gums) is reported as a common side effect in the clinical data for this medication.


Q: What is the specific risk of hyperkalemia associated with the Drospirenone component?

The drospirenone component has a unique action that can slightly increase potassium levels in the blood, known as anti-mineralocorticoid activity. This documented risk is the basis for the medication being contraindicated in individuals with conditions that predispose them to high potassium levels.


Q: What documentation exists regarding Diva Total's use in pediatric populations?

Official documentation indicates that the use of Diva Total is established for postpubertal adolescents who have already started menstruating. The safety and effectiveness profile in this group is reported to be similar to that observed in adults.


Q: Does the efficacy of Diva Total change when taken with food?

Regulatory guidance states that the medicine can be taken without regard to meals and its effectiveness is not impacted by food. Although some professionals suggest taking it after an evening meal or at bedtime, this is primarily to help manage potential nausea.


Q: What are the general expectations for using Diva Total for management of moderate acne?

Clinical trials for acne management generally examined effects over a six-month period, focusing on improvements in lesion counts and overall skin appearance scores. The research applies to women also seeking contraception, and long-term data on sustained skin improvement is noted as limited beyond the initial trial period.

How should Diva Total be stored and disposed of?

How to Store and Dispose of Diva Total?

The official storage and disposal requirements for Diva Total (Drospirenone and Ethinyl Estradiol) are strictly defined to maintain product stability and ensure public safety.

Storage and Disposal Requirement Official Constraints
Temperature & Environment Store at Controlled Room Temperature (20 C to 25 C), away from excess heat, light, and moisture. Do not freeze or store in the bathroom.
Packaging Keep the tablets in the original container, tightly closed.
Child Safety Keep this medication strictly out of the sight and reach of children and pets.
Disposal Do not flush the medication down the toilet. Dispose of unused or expired product via a drug take-back program or by mixing it with an undesirable substance (e.g., dirt, cat litter) in a sealed container before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diva Total found in:

A-Z Index: